TECH
BIO-TECHNE Corp
Overview
Bio-Techne manufactures and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets worldwide.
BIO-TECHNE Corp is a Healthcare company operating in Biotechnology with a $8.71B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2025-11-0517 Q&A exchanges
- Q4 FY2025Earnings2025-08-0620 Q&A exchanges
- Q3 FY2025Earnings2025-05-0717 Q&A exchanges
- Q2 FY2025Earnings2025-02-0533 Q&A exchanges
- Q1 FY2025Earnings2024-10-3020 Q&A exchanges
- Q4 FY2024Earnings2024-08-0719 Q&A exchanges
- Q3 FY2024Earnings2024-05-0118 Q&A exchanges
- Q2 FY2024Earnings2024-02-0117 Q&A exchanges
- Q1 FY2024Earnings2023-10-3120 Q&A exchanges
- Q4 FY2023Earnings2023-08-0814 Q&A exchanges
- Q3 FY2023Earnings2023-05-0322 Q&A exchanges
- Q2 FY2023Earnings2023-02-0213 Q&A exchanges
- Q1 FY2023Earnings2022-11-0124 Q&A exchanges
- Q4 FY2022Earnings2022-08-0613 Q&A exchanges
- Q3 FY2022Earnings2022-05-0415 Q&A exchanges
- Q2 FY2022Earnings2022-02-0125 Q&A exchanges
- Q1 FY2022Earnings2021-11-0227 Q&A exchanges
- Q4 FY2021Earnings2021-08-0724 Q&A exchanges
- Q3 FY2021Earnings2021-05-0930 Q&A exchanges
- Q2 FY2021Earnings2021-02-0220 Q&A exchanges
- Q1 FY2021Earnings2020-11-0822 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-04EPS— vs $0.52—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | — | $0.52 | — | — | — | — | EODHD |
Source: EODHD. TECH reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks TECH's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.75 | $4.08 | +41.0% | -6.7% | -7.9% |
| Q4 FY2026 | $5.62 | $4.29 | +31.0% | -7.2% | -7.8% |
| Q3 FY2026 | $5.89 | $4.26 | +38.2% | +2.7% | +3.6% |
| Q2 FY2026 | $5.91 | $4.33 | +36.5% | +1.3% | +4.1% |
| Q1 FY2025 | $6.02 | $4.24 | +41.9% | -0.6% | -3.0% |
| Q4 FY2025 | $6.19 | $4.36 | +42.0% | -8.1% | -9.5% |
| Q3 FY2025 | $5.80 | $4.37 | +32.8% | -5.5% | -5.8% |
| Q2 FY2025 | $6.04 | $4.29 | +40.7% | +3.4% | +6.4% |
| Q1 FY2024 | $6.21 | $4.42 | +40.4% | +0.8% | -0.4% |
| Q4 FY2024 | $5.97 | $4.38 | +36.4% | +1.7% | +1.3% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Kim KeldermanCEO11 mo9 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- James HippelCFO11 mo21 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance raise Q1 FY2026
- Steven C CrousePresident3 mono recorded callsCurrentSample
PRESIDENT since 2026 • 1/2 beats (50%) • last call held guidance Q1 FY2026
- Matthew McManusPresident10 mono recorded callsCurrentSample
PRESIDENT since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- William GeistPresident10 mo1 callCurrentSample
PRESIDENT since 2025 • 1/4 beats (25%) • last guidance raise Q1 FY2026
- Shane BohnenSVP - General Counsel1 yr 2 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TECH.
$ curl https://api.spokenalpha.com/v1/companies/TECHFAQ
Frequently asked about TECH
Where can I find BIO-TECHNE Corp's (TECH) earnings call transcripts?
Spoken Alpha indexes TECH's earnings call transcripts at https://spokenalpha.com/companies/TECH. Each call links to attributed speakers and parsed analyst Q&A. BIO-TECHNE Corp's own investor relations page is at https://investors.bio-techne.com/.
When was BIO-TECHNE Corp's most recent earnings call?
BIO-TECHNE Corp (TECH) held its most recent earnings call on 2025-11-05, covering fiscal Q1 2026.
What sector is TECH in?
BIO-TECHNE Corp (TECH) operates in the Healthcare sector (Biotechnology industry).